Myotonic dystrophy type 1 is caused by a CTG repeat expansion in the DMPK gene, which follows an autosomal dominant inheritance pattern—a pathogenic expansion in one copy of the gene is sufficient to produce the condition. The molecular mechanism involves expansion of the CTG repeat from the normal range (fewer than 35 repeats) to 50 or more repeats in affected individuals, with some carrying thousands of repeats. The expanded repeat-containing RNA accumulates in nuclear foci within cells and sequesters RNA-binding proteins, impairing their function and disrupting normal splicing and gene regulation across multiple tissues. Expert review confirms that CTG repeat length generally correlates with phenotypic severity category—with larger expansions associated with the congenital form—though the correlation has substantial overlap and repeat size alone is not a reliable sole predictor of phenotypic severity. Penetrance is high, approaching 100% by age 50 when all manifestations, including subtle ones, are evaluated.

The diagnostic approach for myotonic dystrophy type 1 documented in this packet includes CTG repeat analysis of the DMPK gene using PCR and Southern blot techniques, electromyography (EMG) demonstrating myotonic discharges, and clinical evaluation for characteristic features. Slit-lamp examination for posterior subcapsular cataracts is part of the documented diagnostic evaluation. Expert review describes that the condition is suspected in adults presenting with muscle weakness (particularly affecting distal leg, hand, neck, and face muscles), demonstrable myotonia such as grip myotonia or percussion myotonia, and posterior subcapsular cataracts. In neonates, expert review identifies the combination of hypotonia, facial muscle weakness, generalized weakness, positional deformities, and respiratory insufficiency as raising consideration for the congenital form. Expert review notes that consensus-based care recommendations have been published for both adults and for individuals with congenital- and childhood-onset forms of the condition.

No verified FDA-approved treatments are documented in this packet specifically for myotonic dystrophy type 1. The certified foundational management approaches documented for this condition include annual cardiac evaluation with electrocardiogram and Holter monitoring, and pacemaker or implantable cardioverter-defibrillator (ICD) placement for significant cardiac conduction abnormalities. Mexiletine is documented among the certified foundational therapies for symptomatic myotonia; expert review notes that myotonia in DM1 is typically mild to moderate and infrequently requires pharmacologic treatment. Modafinil is included in the certified foundational therapies for excessive daytime sleepiness. Respiratory monitoring and bilevel positive airway pressure (BiPAP) support are documented for individuals with respiratory insufficiency, and cataract surgery is included as a foundational approach when cataracts become visually significant. Expert review notes that statins used for cholesterol reduction may be associated with increased muscle pain and weakness in this condition. Expert review also documents that certain anesthetic agents—including thiopentone, suxamethonium, neostigmine, and halothane—carry elevated perioperative pulmonary risks in individuals with DM1, and that careful perioperative monitoring is a documented aspect of management. Expert review states that no specific treatment exists for the progressive weakness in DM1.

Certified natural history data for myotonic dystrophy type 1 is not provided as a standalone field in this packet. Expert review characterizes the condition as systemic with findings spanning a continuum from mild presentations—sometimes limited to cataracts and mild myotonia—to the severe congenital form associated with respiratory insufficiency and significant motor involvement. Expert review documents three phenotypic categories—mild, classic, and congenital—with generally corresponding CTG repeat size ranges, though overlap is considerable. Penetrance is documented as high, approaching 100% by age 50 when all manifestations, including subtle ones, are assessed. Expert review does not characterize the condition as uniformly progressive at a fixed rate; the clinical course varies substantially across affected individuals.

Numerous certified active trial records are present for myotonic dystrophy type 1, reflecting substantial research activity across multiple domains in this condition. Active clinical trials for this condition are listed on ClinicalTrials.gov.